JP2005501532A5 - - Google Patents

Download PDF

Info

Publication number
JP2005501532A5
JP2005501532A5 JP2003506300A JP2003506300A JP2005501532A5 JP 2005501532 A5 JP2005501532 A5 JP 2005501532A5 JP 2003506300 A JP2003506300 A JP 2003506300A JP 2003506300 A JP2003506300 A JP 2003506300A JP 2005501532 A5 JP2005501532 A5 JP 2005501532A5
Authority
JP
Japan
Prior art keywords
antigens
examples
derived
pathogens
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003506300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005501532A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/017374 external-priority patent/WO2002102828A2/en
Publication of JP2005501532A publication Critical patent/JP2005501532A/ja
Publication of JP2005501532A5 publication Critical patent/JP2005501532A5/ja
Pending legal-status Critical Current

Links

JP2003506300A 2001-06-01 2002-05-31 キメラフラビウイルスベクター Pending JP2005501532A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29526501P 2001-06-01 2001-06-01
PCT/US2002/017374 WO2002102828A2 (en) 2001-06-01 2002-05-31 Chimeric flavivirus vectors

Publications (2)

Publication Number Publication Date
JP2005501532A JP2005501532A (ja) 2005-01-20
JP2005501532A5 true JP2005501532A5 (enExample) 2010-03-25

Family

ID=23136958

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003506300A Pending JP2005501532A (ja) 2001-06-01 2002-05-31 キメラフラビウイルスベクター

Country Status (11)

Country Link
US (2) US7569383B2 (enExample)
EP (1) EP1401859B1 (enExample)
JP (1) JP2005501532A (enExample)
KR (1) KR100921592B1 (enExample)
CN (1) CN1551782A (enExample)
AU (1) AU2002322026B2 (enExample)
BR (1) BR0210907A (enExample)
CA (1) CA2448971C (enExample)
ES (1) ES2439724T3 (enExample)
PL (1) PL371187A1 (enExample)
WO (1) WO2002102828A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
PL371187A1 (en) 2001-06-01 2005-06-13 Acambis, Inc. Chimeric flavivirus vectors
US20050002968A1 (en) * 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
JP2005519639A (ja) 2002-01-15 2005-07-07 アカンビス インコーポレーティッド フラビウイルスワクチン
AU2003239932A1 (en) * 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
AU2003290985B2 (en) 2002-11-15 2010-04-01 Acambis Inc. West nile virus vaccine
RU2009105099A (ru) * 2006-07-14 2010-08-27 Санофи Пастер Байолоджикс Ко. (Us) Конструирование рекомбинантных вирусных вакцин путем прямой транспозон-опосредованной инсерции чужеродных иммунологических детерминант в белки векторного вируса
KR20090096414A (ko) * 2006-09-29 2009-09-10 사노피 파스테르 바이오로직스 씨오 재조합 리노바이러스 벡터
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
CA2668834C (en) 2006-11-07 2016-10-11 Sanofi Pasteur Biologics Co. Stabilization of vaccines by lyophilization
EP2117589A4 (en) * 2007-01-31 2010-07-21 Sanofi Pasteur Biologics Co FLAVIVIRUS VACCINE VECTOR AGAINST INFLUENZA VIRUS
WO2009030872A1 (en) * 2007-09-07 2009-03-12 Mats Axel Atterdag Persson Materials and methods for the treatment of hepatitis c
ES2615390T3 (es) 2008-03-05 2017-06-06 Sanofi Pasteur Proceso para estabilizar una composición de vacuna que contiene adyuvante
JP5779352B2 (ja) 2008-03-14 2015-09-16 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 複製欠損フラビウイルスワクチンおよびワクチンベクター
JP2011517408A (ja) * 2008-03-27 2011-06-09 サノフィ パスツール バイオロジクス カンパニー 組換えライノウイルスベクター
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
EP2408477A4 (en) * 2009-03-16 2013-03-27 Sanofi Pasteur Biologics Llc REPLICATION DEFECTS FLAVIVIRUS VACCINE VACCINATORS AGAINST RESPIRATORY SYNZYTIAL VIRUS
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
BR112014009887A2 (pt) * 2011-10-25 2017-04-25 Florida Gulf Coast Univ vacinmas e métodos para desenvolvimento de vacina para indução de imunidade a todos os sorotipos de virus da dengue
MY168959A (en) 2012-07-24 2019-01-28 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
CA2878599A1 (en) * 2012-07-24 2014-01-30 Jiansheng Yao Vaccine compositions for prevention against dengue virus infection
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
CN103352029A (zh) * 2013-07-29 2013-10-16 中国人民解放军军事医学科学院微生物流行病研究所 一种乙脑/森林脑炎嵌合病毒及其应用
US10428313B2 (en) 2014-06-20 2019-10-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric West Nile/Dengue viruses and methods of use
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
US10857222B2 (en) 2015-07-03 2020-12-08 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
BR112019019813A2 (pt) 2017-03-30 2020-04-22 The University Of Queensland moléculas quiméricas e usos das mesmas
EP3687561A4 (en) 2017-09-01 2021-06-09 The Australian National University "immunoregulatory molecules and uses therefor"
AU2018346724B2 (en) 2017-10-05 2025-01-09 Sanofi Pasteur Compositions for booster vaccination against dengue
US20220168412A1 (en) * 2019-04-10 2022-06-02 Katholieke Universiteit Leuven Chimeric Zika-Japanese Encephalitis Virus
CN111798712B (zh) * 2020-07-15 2021-10-29 周晓庆 噬菌体侵染细菌3d智能模拟方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
DE69230316T2 (de) 1991-09-19 2000-07-13 Us Health Chimäre und/oder wachstumsgehemmte flaviviren
US6136561A (en) 1995-05-24 2000-10-24 Hawaii Biotechnology Group, Inc. Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
CA2282790C (en) 1997-02-28 2011-04-19 St. Louis University Chimeric flavivirus vaccines
BRPI9701774B8 (pt) 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US6416763B1 (en) 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
US6416783B1 (en) * 1999-08-20 2002-07-09 Wisconsin Alumni Research Foundation Aspartic and malic acid inhibition of ss-glucuronidase
AU1813901A (en) 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
GB2372991B (en) * 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
PL371187A1 (en) 2001-06-01 2005-06-13 Acambis, Inc. Chimeric flavivirus vectors
US6682883B1 (en) 2001-07-19 2004-01-27 Acambis, Inc. Diagnosis of flavivirus infection
DK1441761T3 (da) 2001-10-19 2007-08-27 Acambis Inc Fremgangsmåder til forebyggelse og behandling af flavivirus-infektion hos dyr
US20050002968A1 (en) 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
JP2005519639A (ja) 2002-01-15 2005-07-07 アカンビス インコーポレーティッド フラビウイルスワクチン
AU2003239932A1 (en) 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
AU2003290985B2 (en) 2002-11-15 2010-04-01 Acambis Inc. West nile virus vaccine
US7189403B2 (en) 2003-06-30 2007-03-13 Institut Pasteur Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
WO2005040390A1 (en) 2003-07-21 2005-05-06 Shanghai Tengen Biomedical Co., Ltd. A recombinant vaccine using yellow fever virus as vector
WO2005049815A1 (en) 2003-11-21 2005-06-02 K.U.Leuven Research & Development Flavivirus replication
WO2006044857A2 (en) 2004-10-20 2006-04-27 Acambis Inc. Vaccines against japanese encephalitis virus and west nile virus
CN103031279B (zh) 2005-04-24 2015-11-18 赛诺菲巴斯德生物制药有限责任公司 重组黄病毒疫苗
BRPI0504945B8 (pt) 2005-10-31 2022-08-02 Fundacao Oswaldo Cruz Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.

Similar Documents

Publication Publication Date Title
UA85536C2 (en) Viral antigens
DK1113816T3 (da) Influenzavirus-vaccinesammensætning
JP2004524889A5 (enExample)
EP2275131A3 (en) HCV Vaccines
ATE275631T1 (de) Rekombinanter venezolanische-equine- pferdeenzephalitis-virusimpstoff
JP2004538039A5 (enExample)
JP2005502322A5 (enExample)
EP1741782A3 (en) Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
JP2002524024A5 (enExample)
IL202249A (en) Nucleic Acids Encoders Human Immunodeficiency Strange Type 1 (HIV – 1) Group M Consensus Envelope Glycoproteins
ATE257175T1 (de) Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus
JP2003160581A5 (enExample)
EP2368576A3 (en) Functionally reconstituted viral membranes containing adjuvant
EP2290091A3 (en) Recombinant measles viruses expressing epitopes of antigens of RNA viruses and use of the recombinant viruses for the preparation of vaccine compositions
JP2005511495A5 (enExample)
ATE455791T1 (de) T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon
DE60330966D1 (de) Rekombinante vesicular stomatitis viren als impstoff gegen virale hämorrhagische fieber
DE60042816D1 (de) T-helferzellen-epitope
EP1399481A4 (en) RECOMBINANT ANTIBODIES TO INFECTIOUS BURSAL DISEASE VIRUS (IBDV)
JP2003514090A5 (enExample)
JP2005534326A5 (enExample)
ATE437656T1 (de) Impfstoff gegen das maul- und klauensäure-virus
JP2007516701A5 (enExample)
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
AU2002952524A0 (en) Epstein barr virus peptide epitopes